John Evans
@john_evans3
Followers
8K
Following
7K
Media
108
Statuses
4K
CEO, Beam Therapeutics. We are working on creating precision genetic medicines using base editing. (tweets are my own)
Joined February 2012
Wonderful NYT story about our BEAM-302 data in @nytimes. @ginakolata provides a clear summary of the significance of this data, along with perspectives from leaders in the AATD and genetic disease fields. We will accelerate this program for patients .
nytimes.com
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely targeted infusions.
5
6
32
RT @EliLillyandCo: What if science could completely change the treatment of cardiovascular disease—from chronic care to a one-and-done trea….
0
7
0
Great progress at Orbital using targeted LNPs for in vivo delivery to T cells — happy to be partnered and supporting this exciting therapeutic approach:.
Circular RNA startup Orbital unveils first monkey data as it enters in vivo CAR-T cell therapy race - via @endpts @RLCscienceboss.
2
1
18
Congrats Sek, @VerveTx, and @EliLillyandCo !. A powerhouse combination in cardiovascular health:.
Today, we are thrilled to announce that @VerveTx has entered into a definitive agreement to be acquired by @EliLillyandCo. From 2018 to 2025, Verve moved a new concept (a one-dose future for the treatment of atherosclerotic cardiovascular disease) and a new medical technology (in
1
2
46
RT @BeamTx: Beam announced new safety & efficacy data from its BEACON Phase 1/2 clinical trial of BEAM-101 in patients with sickle cell dis….
0
7
0
RT @SecKennedy: Thursday morning, I had the privilege of speaking with the Muldoon family, whose 10-month-old son, baby KJ, was discharged….
0
866
0
RT @BowTiedBiotech: 🧬 FDA Cell & Gene Therapy Roundtable: A Story of Frustration, Urgency, and Hope 🧵. Today, something rare happened. The….
0
44
0
Another inspiring update on the KJ story. We say that base editing is “programmable” — that is just another way of saying it is both “customizable” and “predictable”. Progress in gene editing will make more outcomes like this possible.
A baby who is the first patient in the world to be successfully treated with customized CRISPR gene editing therapy is finally returning home from the hospital.
1
11
52
RT @Carolynyjohnson: In case you needed a smile this Tuesday: 10-month-old baby KJ, who received a bespoke gene-editing therapy after a six….
0
67
0
RT @davidrliu: In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, stud….
0
431
0
RT @RLCscienceboss: BREAKING: Last August, scientists secretly began creating a custom #CRISPR therapy to fix a mutation responsible for on….
endpoints.news
Two researchers have been working to rapidly design custom CRISPR treatments for rare diseases that profit-driven drug companies have left behind. But one child's dire condition provided an opportu...
0
15
0
Ultimately, that rapid adaptability supports a vision of customized therapies, as shown here for the first time in gene editing. It will also require close partnership -- with industry, regulators, doctors, hospitals, payers, and patients & families all working together.
0
0
11
One of the most powerful things about genetic technologies like base editing is that as they advance, they also become ever easier to adapt to new targets. At Beam, our next base editing programs for liver or blood diseases will be vastly simpler to create than our first ones.
1
1
15
RT @adamfeuerstein: CRISPR is used in landmark treatment to correct genetic misspelling of a single patient via @Ja….
statnews.com
In a world first, scientists used CRISPR to fix a baby's unique genetic mutation. The report offers hope for personalized treatments of rare diseases.
0
21
0
Beautiful story here about a customized base editing treatment for a newborn baby with a life threatening genetic disease. Congratulations to @kiranmusunuru, Rebecca Ahrens-Nicklas, @UrnovFyodor, and the rest of the team that made this happen.
Breaking News: A baby with a rare disorder made medical history by receiving the first custom gene-editing treatment. The technique used has the potential to help people with thousands of other uncommon genetic diseases.
2
15
65
RMAT is an innovative FDA program that allows closer coordination between sponsor and agency with the goal of accelerating the development of promising therapeutics for patients with high unmet need.
0
0
10
Very pleased to announce that BEAM-302 for Alpha-1 Antitrypsin Deficiency has been granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA!.
globenewswire.com
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines...
7
15
99
RFK: HHS “has a deep commitment to ensuring access for Medicaid beneficiaries to next-generation therapies.”. For too many Americans with rare diseases, healthier lifestyle choices aren’t enough. MAHA is here to help them, too. The MAHA team is going to revolutionize healthcare
1
1
2
This announcement is revolutionary for Americans suffering from rare chronic diseases across the country. RFK: “Sickle cell disease is a terrible illness.”. “I have many friends who have it, and their lives are devastated. They oftentimes live in agony.”. “This is a community
1
0
5
@SecKennedy @SecKennedy.@HHS has a “deep commitment to ensuring access for Medicaid beneficiaries to next generation therapies, and particularly those like the gene therapies for sickle cell disease, which can address the root cause of chronic disease and transform the life of beneficiaries”.
1
0
6